Immunoglobulin G responses against human papillomavirus type 16 virus- like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia

Journal of the National Cancer Institute

Volumn 89, Issue 9, 1997, Pages 630-638

  De Gruijl, Tanja D ^a   Bontkes, Hetty J ^a   Walboomers, Jan M M ^a   Schiller, John T ^c   Stukart, Marij J ^a   Groot, Bart S ^a   Chabaud, Martine M R ^b   Remmink, Ans J ^a   Verheijen, René H M ^a   Heimerhorst, Theo J M ^a   Meijer, Chris J L M ^a   Scheper, Rik J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITÉ DE TOURS   (France)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G;

ADULT; ANTIBODY RESPONSE; ARTICLE; CANCER RISK; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PERSISTENT VIRUS INFECTION; PRECANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DYSPLASIA; VIRUS INFECTION; VIRUS PARTICLE; VIRUS TYPING; WART VIRUS;

EID: 0031008091     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.9.630     Document Type: Article

References (30)

1. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
2. IARC. Monographs on the Evaluation of the Carcinogenic Risks to Humans, vol 64, the Human Papillomavirus. Lyon: International Agency for Research on Cancer, 1995.
3. zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. In: zur Hausen H, editor. Human pathogenic papillomaviruses. Heidelberg and New York: Springer-Verlag Berlin, 1994:131-56.
4. Schafer A, Friemann W, Mielke M, Schwartlander B, Koch MA. The increased frequency of cervical dysplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression. Am J Obstet Gynecol 1991;164:593-9.
5. Halpert R, Fruchter RG, Sedlis A, Butt K, Boyce JG, Sillman FH. Human papillomavirus and lower genital neoplasia in renal transplant patients. Obstet Gynecol 1986;68:251-8.
6. Laga M, Icenogle JP, Marsella R, Manoka AT, Nzila N, Ryder RW, et al. Genital papillomavirus infection and cervical dysplasia - opportunistic complications of HIV infection. Int J Cancer 1992;50:45-8.
7. Remmink AJ, Walboomers JM, Heimerhorst TJ, Voorhorst FJ, Rozendaal L, Risse EK, et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer 1995;61:306-11.
8. Wikstrom A, van Doornum GJ, Quint WG, Schiller JT, Dillner J. Identification of human papillomavirus seroconversions. J Gen Virol 1995; 76:529-39.
9. Andersson-Ellstrom A, Dillner J, Hagmar B, Schiller J, Forssman L. HPV-16 transmission - authors' reply. Lancet 1995;345:197-8.
10. Carter JJ, Koutsky LA, Wipf GC, Christensen ND, Lee SK, Kuypers J, et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 1996;174:927-36.
11. Lowy DR, Kirnbauer R, Schiller JT. Genital human papillomavirus infection. Proc Natl Acad Sci U S A 1994;91:2436-40.
12. Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, Gissmann L, et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 1993;67:6929-36.
13. Le Cann P, Touze A, Enogat N, Leboulleux D, Mougin C, Legrand MC, et al. Detection of antibodies against human papillomavirus (HPV) type 16 virions by enzyme-linked immunosorbent assay using recombinant HPV16 L1 capsids produced by recombinant baculovirus. J Clin Microbiol 1995;33:1380-2.
14. Le Cann P, Coursaget P, Iochmann S, Touze A. Self-assembly of human papillomavirus type 16 capsids by expression of the L1 protein in insect cells. FEMS Microbiol Lett 1994;117:269-74.
15. Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 1994;86:494-9.
16. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth C, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995;69:3959-63.
17. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995;92:11553-7.
18. Kirnbauer R, Chandrachud LM, O'Neil BW, Wagner ER, Grindlay GJ, Armstrong A, et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 1996;219:37-44.
19. van den Brule AJ, Meijer CJ, Bakels V, Kenemans P, Walboomers JM. Rapid detection of human papillomavirus in cervical scrapes by combined general primer-mediated and type-specific polymerase chain reaction. J Clin Microbiol 1990;28:2739-43.
20. de Roda Husman AM, Walboomers JM, Meijer CJ, Risse EK, Schipper ME, Helmerhorst TJ, et al. Analysis of cytomorphologically abnormal cervical scrapes for the presence of 27 mucosotropic human papillomavirus genotypes, using polymerase chain reaction. Int J Cancer 1994;56:802-6.
21. Wideroff L, Schiffman MH, Nonnenmacher B, Hubbert N, Kirnbauer R, Greer CE, et al. Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis 1995;172:1425-30.
22. Roden RB, Hubbert NL, Kirnbauer R, Christensen ND, Lowy DR, Schiller JT. Assessment of the serological relatedness of genital human papilloma-viruses by hemagglutination inhibition. J Virol 1996;70:3298-301.
23. Dillner J, Kallings I, Brihmer C, Sikstrom B, Koskela P, Lehtinen M, et al. Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis 1996;173:1394-8.
24. Nonnenmacher B, Hubbert NL, Kirnbauer R, Shah KV, Munoz N, Bosch FX, et al. Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain. J Infect Dis 1995;172:19-24.
25. Lehtinen M, Dillner J, Knekt P, Luostarinen T, Aromaa A, Kirnbauer R, et al. Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study. BMJ 1996;312:537-9.
26. Schiller JT, Roden RB. Papillomavirus-like particles. Papillomavirus Rep 1995;6:121-8.
27. Stoler MH, Rhodes CR, Whitbeck A, Wolinsky SM, Chow LT, Broker TR. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol 1992;23:117-28.
28. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235-40.
29. Jacobs MV, van den Brule AJ, Snijders PJ, Helmerhorst TJ, Meijer CJ, Walboomers JM. A non-radioactive PCR enzyme-immunoassay enables a rapid identification of HPV 16 and 18 in cervical scrapes after GP5+/6+ PCR. J Med Virol 1996;49:223-9.
30. Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 1995;171:1387-98.